| Mark Paul Garrett, MD | |
|
1875 W Frye Rd Ste 300, Chandler, AZ 85224-6184 | |
| (480) 917-5600 | |
| (602) 294-4497 |
| Full Name | Mark Paul Garrett |
|---|---|
| Gender | Male |
| Speciality | Neurosurgery |
| Experience | 19 Years |
| Location | 1875 W Frye Rd Ste 300, Chandler, Arizona |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1669652699 | NPI | - | NPPES |
| 701962 | Medicaid | AZ |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207T00000X | Neurological Surgery | 42498 (Arizona) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Chandler Regional Medical Center | Chandler, AZ | Hospital |
| Mercy Gilbert Medical Center | Gilbert, AZ | Hospital |
| Dignity Health Arizona General Hospital | Mesa, AZ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Neurosurgical Associates Ltd | 8820993967 | 78 |
News Archive
A personalized tumor cell vaccine strategy targeting Myc oncogenes combined with checkpoint therapy creates an effective immune response that bypasses antigen selection and immune privilege, according to a pre-clinical study for neuroblastoma and melanoma.
The rapidly ageing population is bringing new challenges to European society. Care institutions and hospitals are facing serious staffing shortages, as fewer and fewer people choose to become healthcare professionals, while at the same time the number of old (and sick) people is constantly on the rise.
VaxGen, Inc., a biopharmaceutical company, and diaDexus, Inc., a privately held diagnostics company focused on the development and commercialization of patent-protected in vitro diagnostic products addressing unmet needs in cardiovascular disease, announced today that they have entered into a definitive agreement under which VaxGen will acquire diaDexus in a stock-for-stock merger.
Orgenesis Inc., a leading cell and gene therapy enabling company providing centralized CDMO manufacturing and development services through its subsidiary Masthercell Global, Inc., as well as localized point-of-care development and processing centers for therapeutic treatments, today announces a strategic partnership agreement between the HYGEIA Group and the Theracell–Orgenesis joint venture.
CPEX Pharmaceuticals, Inc. ("CPEX") today announced that it will participate in the Ninth Annual Diabetes Technology Meeting to be held November 5–7, 2009, at the Hyatt Regency Airport in San Francisco, California. Dr. Lance Berman, Senior Vice President and Chief Medical Officer, is scheduled to present an oral presentation titled "The Technology and Clinical Aspects of Nasal Insulin Therapy" at 9:30 a.m. PST on Saturday, November 7, 2009.
› Verified 5 days ago
| Entity Name | Neurosurgical Associates Ltd |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043202484 PECOS PAC ID: 8820993967 Enrollment ID: O20031203000219 |
News Archive
A personalized tumor cell vaccine strategy targeting Myc oncogenes combined with checkpoint therapy creates an effective immune response that bypasses antigen selection and immune privilege, according to a pre-clinical study for neuroblastoma and melanoma.
The rapidly ageing population is bringing new challenges to European society. Care institutions and hospitals are facing serious staffing shortages, as fewer and fewer people choose to become healthcare professionals, while at the same time the number of old (and sick) people is constantly on the rise.
VaxGen, Inc., a biopharmaceutical company, and diaDexus, Inc., a privately held diagnostics company focused on the development and commercialization of patent-protected in vitro diagnostic products addressing unmet needs in cardiovascular disease, announced today that they have entered into a definitive agreement under which VaxGen will acquire diaDexus in a stock-for-stock merger.
Orgenesis Inc., a leading cell and gene therapy enabling company providing centralized CDMO manufacturing and development services through its subsidiary Masthercell Global, Inc., as well as localized point-of-care development and processing centers for therapeutic treatments, today announces a strategic partnership agreement between the HYGEIA Group and the Theracell–Orgenesis joint venture.
CPEX Pharmaceuticals, Inc. ("CPEX") today announced that it will participate in the Ninth Annual Diabetes Technology Meeting to be held November 5–7, 2009, at the Hyatt Regency Airport in San Francisco, California. Dr. Lance Berman, Senior Vice President and Chief Medical Officer, is scheduled to present an oral presentation titled "The Technology and Clinical Aspects of Nasal Insulin Therapy" at 9:30 a.m. PST on Saturday, November 7, 2009.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mark Paul Garrett, MD 2910 N 3rd Ave # 200, Phoenix, AZ 85013-4434 Ph: (480) 917-5600 | Mark Paul Garrett, MD 1875 W Frye Rd Ste 300, Chandler, AZ 85224-6184 Ph: (480) 917-5600 |
News Archive
A personalized tumor cell vaccine strategy targeting Myc oncogenes combined with checkpoint therapy creates an effective immune response that bypasses antigen selection and immune privilege, according to a pre-clinical study for neuroblastoma and melanoma.
The rapidly ageing population is bringing new challenges to European society. Care institutions and hospitals are facing serious staffing shortages, as fewer and fewer people choose to become healthcare professionals, while at the same time the number of old (and sick) people is constantly on the rise.
VaxGen, Inc., a biopharmaceutical company, and diaDexus, Inc., a privately held diagnostics company focused on the development and commercialization of patent-protected in vitro diagnostic products addressing unmet needs in cardiovascular disease, announced today that they have entered into a definitive agreement under which VaxGen will acquire diaDexus in a stock-for-stock merger.
Orgenesis Inc., a leading cell and gene therapy enabling company providing centralized CDMO manufacturing and development services through its subsidiary Masthercell Global, Inc., as well as localized point-of-care development and processing centers for therapeutic treatments, today announces a strategic partnership agreement between the HYGEIA Group and the Theracell–Orgenesis joint venture.
CPEX Pharmaceuticals, Inc. ("CPEX") today announced that it will participate in the Ninth Annual Diabetes Technology Meeting to be held November 5–7, 2009, at the Hyatt Regency Airport in San Francisco, California. Dr. Lance Berman, Senior Vice President and Chief Medical Officer, is scheduled to present an oral presentation titled "The Technology and Clinical Aspects of Nasal Insulin Therapy" at 9:30 a.m. PST on Saturday, November 7, 2009.
› Verified 5 days ago
Steve Won-tze Chang, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 1875 W Frye Rd Ste 300, Chandler, AZ 85224 Phone: 602-406-3112 Fax: 602-406-4187 | |
Tsinsue Chen, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 1875 W Frye Rd Ste 300, Chandler, AZ 85224 Phone: 480-917-5600 Fax: 602-294-8291 | |
Taro Kaibara, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 1875 W Frye Rd Ste 300, Chandler, AZ 85224 Phone: 480-917-5600 Fax: 602-294-4494 | |
David J Fusco, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 1875 W Frye Rd Ste 300, Chandler, AZ 85224 Phone: 480-917-5600 Fax: 602-294-4499 | |
Dr. Kaith K. Almefty, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 1875 W Frye Rd Ste 300, Chandler, AZ 85224 Phone: 480-917-5600 Fax: 602-294-8289 |